Alkermes long-acting schizophrenia drug under FDA scrutiny
This article was originally published in Scrip
Executive Summary
If all goes well for Alkermes, it could have a decision in hand from the FDA by 22 August 2015 on the company's new drug application (NDA) for aripiprazole lauroxil, a once-monthly, long-acting injectable atypical antipsychotic.